Please login to the form below

Not currently logged in

AstraZeneca’s Brilinta reduces rate of secondary stroke

Drug helps to prevent rate of stroke and death by 17%


AstraZeneca’s Brilinta reduced the rate of stroke and death by 17% in patients who had previously experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack (TIA).

Detailed results from the phase 3 THALES trial also showed that Brilinta, given at a dose of 90mg twice-daily alongside aspirin, significantly reduced the rate of ischaemic stroke by 21%, compared to aspirin alone. The drug also reduced the risk for severe bleeding events – in the aspirin group the rate was 0.5%, while in the Brilinta treatment group it was just 0.1%.

“Patients who had an acute ischaemic stroke or transient ischaemic attack may experience a subsequent, potentially avoidable stroke. Results from the phase 3 THALES trial confirm that aspirin plus Brilinta has the potential to be a new effective treatment option for these high-risk patients and we look forward to continuing discussions with regulatory authorities,” said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AZ.

The positive results make up for previous disappointing data for Brilinta (ticagrelor) in this prevention setting – in 2016, Brilinta administered alone failed to show a significant benefit in reducing the rate of stroke and death in the same indication.

The results of the SOCRATES trial revealed that Brilinta, given at a dose of 90mg twice-daily, was no more effective than a single daily dose of aspirin in preventing stroke, heart attack and/or death when given to patients who had previously suffered a stroke or transient transient ischaemic attack.

The P2Y12 receptor agonist has been an important growth product for AZ and although it had a slow start, has been stacking up research in prevention indications from coronary artery disease to type 2 diabetes. Those indications helped the drug to deliver sales of $1.6bn in 2019, which constitutes a 23% growth over the year driven in particular by a strong performance in emerging markets.

The drug is already approved for the treatment of acute coronary syndrome (ACS) and for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.

The US Food and Drug Administration (FDA) has already accepted a supplemental new drug application (sNDA) and granted a priority review for Brilinta for the reduction of subsequent stroke in patients who have previously experienced an acute ischaemic stroke or TIA based on the THALES trial.

According to AZ, an action date for this application is due in the fourth quarter, meaning it could launch Brilinta in this indication before the end of the year.

Article by
Lucy Parsons

16th July 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....